<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37479187</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>334</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Genetic characterization and molecular evolution of type 3 vaccine-derived polioviruses from an immunodeficient patient in China.</ArticleTitle><Pagination><StartPage>199177</StartPage><MedlinePgn>199177</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">199177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2023.199177</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(23)00139-9</ELocationID><Abstract><AbstractText>In 2013, a case of immunodeficiency vaccine-derived poliovirus (iVDPV) was identified in Jiangxi Province, China. In this study, we purified 14 type 3 original viral isolates from this case and characterized the molecular evolution of these iVDPVs for 298 days. Genetic variants were found in most of the original viral isolates, with complex genetic and evolutionary relationships among the variants. A phylogenetic tree constructed based on the P1 region showed that these iVDPVs were classified into lineage A and B. The dominant lineage B represents a major trend in virus evolution. The nucleotide substitution rate at the third codon position (3CP) estimated by the BEAST program was 1.76 × 10<sup>-2</sup> substitutions/site/year (95% HPD: 1.23-2.39 × 10<sup>-2</sup>). The initial OPV dose was given dating back to March 2013, which was close to the time of the last OPV vaccination, suggesting that OPV infection may have originated with the last dose of vaccine. Recombinant analysis showed that these iVDPVs were inter-vaccine recombinants with two recombination patterns, S3/S2/S1 and S3/S2/S3/S2/S1. Whole genome sequence analysis revealed that key nucleotide sites (C472U, C2034U, U2493C) associated with the attenuated phenotype of Sabin 3 have been replaced. Temperature sensitivity test showed that all tested strains were temperature-sensitive, except for the variant Day11-5. Interestingly, we observed that the variant Day11-5 temperature resistance properties may be associated with the Lys to Met substitution at the VP2-162 site. Serological test and whole genome sequence analysis showed that the seropositivity rate remained high, and mutations in the antigenic sites did not significantly alter neutralization ability.</AbstractText><CopyrightInformation>Copyright © 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China; Da Zhou Vocational College of Chinese Medicine, Dazhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shuangli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongyan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Jiangxi Center for Disease Control and Prevention, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Jiangxi Center for Disease Control and Prevention, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hehe</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Huanhuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jinbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Liheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Public Health and Management, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health and Management, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jichen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing, China. Electronic address: dongmeiyan1976@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019143" MajorTopicYN="N">Evolution, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Genetic characterization</Keyword><Keyword MajorTopicYN="N">Immunodeficiency</Keyword><Keyword MajorTopicYN="N">Molecular evolution</Keyword><Keyword MajorTopicYN="N">Oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>22</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37479187</ArticleId><ArticleId IdType="pmc">PMC10388201</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2023.199177</ArticleId><ArticleId IdType="pii">S0168-1702(23)00139-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shaghaghi M., Shahmahmoodi S., Nili A., et al. Vaccine-derived poliovirus infection among patients with primary immunodeficiency and effect of patient screening on disease outcomes, Iran. Emerg. Infect. Dis. 2019;25:2005–2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810208</ArticleId><ArticleId IdType="pubmed">31625840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J., Campagnoli R., De L., Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J. Virol. 2008;82:4429–4440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293050</ArticleId><ArticleId IdType="pubmed">18287242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Wang H., Zhu S., et al. Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis. J. Gen. Virol. 2010;91:421–429.</Citation><ArticleIdList><ArticleId IdType="pubmed">19846676</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Dunn G, Evans DM, et al. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J. Gen. Virol. 1989;70:1117–1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">2543771</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales M, Tangermann RH, SG W. Progress Toward Polio Eradication - Worldwide, 2015-2016. MMWR Morb. Mortal. Wkly. Rep. 2016;65:470–473. May 13.</Citation><ArticleIdList><ArticleId IdType="pubmed">27171208</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M., Shahmahmoodi S., Abolhassani H., et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995-2014. Emerg. Infect. Dis. 2016;22:1712–1719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038407</ArticleId><ArticleId IdType="pubmed">27648512</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkova EA, Gmyl AP, Yakovenko ML, et al. A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin 2 vaccine poliovirus. J. Virol. 2016;90:5978–5988. Jun 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907227</ArticleId><ArticleId IdType="pubmed">27099315</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Diop OM, Humayun A, et al. Update on immunodeficiency-associated vaccine-derived polioviruses - Worldwide, July 2018-December 2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69:913–917. Jul 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffett DB;, Llewellyn A, Singh H, et al. Progress toward poliovirus containment implementation - worldwide, 2019-2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:1330–1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498175</ArticleId><ArticleId IdType="pubmed">32941411</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Wilkinson AL, Tallis G, Burns CC, Wassilak SGF. Progress toward polio eradication - worldwide, January 2019-June 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1129–1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389387</ArticleId><ArticleId IdType="pubmed">34437527</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S. History of vaccination. Proc. Natl. Acad. Sci. U. S. A. 2014;111:12283–12287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151719</ArticleId><ArticleId IdType="pubmed">25136134</ArticleId></ArticleIdList></Reference><Reference><Citation>Diop OM, Burns CC, Wassilak SG. Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013. MMWR Morb. Mortal. Wkly. Rep. 2014;63:242–248. Mar 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584635</ArticleId><ArticleId IdType="pubmed">24647401</ArticleId></ArticleIdList></Reference><Reference><Citation>Endegue-Zanga M.C., Sadeuh-Mba S.A., Iber J., et al. Circulating vaccine-derived polioviruses in the extreme north region of Cameroon. J. Clin. Virol. 2015;62:80–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">25542478</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived polioviruses - worldwide, January 2017-June 2018. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1189–1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6290814</ArticleId><ArticleId IdType="pubmed">30359342</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Shaw J., Jorba J., et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J. Virol. 2013;87:4907–4922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005;59:587–635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM;, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. World Health Organ. 2004;82:16–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585883</ArticleId><ArticleId IdType="pubmed">15106296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jr Alexander JP, Jr Gary HE, MA P. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 1997;175:S176–S182.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203713</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J., Odoom K., Tuite G., et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 2004;78:13839–13847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC533926</ArticleId><ArticleId IdType="pubmed">15564492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Yan D., Zhu S., et al. Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in china: current immunization strategy effectively prevented its sustained transmission. J. Infect. Dis. 2010;202:1780–1788.</Citation><ArticleIdList><ArticleId IdType="pubmed">21050127</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttinelli G., Donati V., Fiore S., et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 2003;84:1215–1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">12692287</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio Bulletin 2022 Issue No. 14 - Week 27 See https://apps.who.int/iris/handle/10665/350978?search-result=true&amp;query=Polio+bulletin+2022&amp;scope=&amp;rpp=10&amp;sort_by=score&amp;order=desc for further details. Accessed 4 July 2022.</Citation></Reference><Reference><Citation>Kitamura K., Shimizu H. The molecular evolution of Type 2 vaccine-derived polioviruses in individuals with primary immunodeficiency diseases. Viruses. 2021;13:1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8310373</ArticleId><ArticleId IdType="pubmed">34372613</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO polio laboratory manual See http://polioeradication.org/wp-content/uploads/2017/05/Polio_Lab_Manual04.pdf for further details. Accessed November 2004.</Citation></Reference><Reference><Citation>Zhao H., Ma X., Tang H., et al. Circulation of Type 2 vaccine-derived poliovirus in China in 2018-2019. Open Forum Infect. Dis. 2021;8:ofab535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8677525</ArticleId><ArticleId IdType="pubmed">34926714</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Zhang Y., Fan Q., et al. Phylogenetic characterizations of highly mutated EV-B106 recombinants showing extensive genetic exchanges with other EV-B in Xinjiang, China. Sci. Rep. 2017;7:43080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322377</ArticleId><ArticleId IdType="pubmed">28230168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D., Wang D., Zhang Y., et al. Implication of a high risk for Type 2 vaccine-derived poliovirus emergence and transmission after the switch from trivalent to bivalent oral poliovirus vaccine. J. Infect. Dis. 2021;223:113–118.</Citation><ArticleIdList><ArticleId IdType="pubmed">32621746</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived polioviruses - worldwide, January 2016-June 2017. MMWR Morb. Mortal. Wkly. Rep. 2017;66:1185–1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5689216</ArticleId><ArticleId IdType="pubmed">29095803</ArticleId></ArticleIdList></Reference><Reference><Citation>Initiative I.S.M.G.o.t.G.P.E. Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine - worldwide, 2013-2016. MMWR Morb. Mortal. Wkly. Rep. 2015;64:699–702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584682</ArticleId><ArticleId IdType="pubmed">26135591</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.F., Chen H.Y., Jorba J., et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 2005;79:12623–12634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235840</ArticleId><ArticleId IdType="pubmed">16188964</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahmahmoodi S., Parvaneh N., Burns C., et al. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res. 2008;137:168–172.</Citation><ArticleIdList><ArticleId IdType="pubmed">18674576</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ;, Arnold C;, Howlett J, et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology. 1989;172:408–414.</Citation><ArticleIdList><ArticleId IdType="pubmed">2552655</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 1989;63:1338–1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247831</ArticleId><ArticleId IdType="pubmed">2536836</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkova E.A., Prostova M.A., Gmyl A.P., et al. Case of poliomyelitis caused by significantly diverged derivative of the poliovirus type 3 vaccine Sabin strain circulating in the orphanage. Viruses. 2020;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7552002</ArticleId><ArticleId IdType="pubmed">32883046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilipenko EV, Blinov VM, Romanova LI, Sinyakov AN, Maslova SV;, VI A. Conserved structural domains in the 5′-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence. Virology. 1989;168:201–209.</Citation><ArticleIdList><ArticleId IdType="pubmed">2536978</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J.Q., Townsend H.L., Jha B.K., Paranjape J.M., Silverman R.H., Barton D.J. A phylogenetically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNase L. J. Virol. 2007;81:5561–5572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900262</ArticleId><ArticleId IdType="pubmed">17344297</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrill C.P., Westesson O., Schulte M.B., Strings V.R., Segal M., Andino R. Global RNA structure analysis of poliovirus identifies a conserved RNA structure involved in viral replication and infectivity. J. Virol. 2013;87:11670–11683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807356</ArticleId><ArticleId IdType="pubmed">23966409</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkova E., Laassri M., Zagorodnyaya T., et al. Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications. Viruses. 2017;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5707560</ArticleId><ArticleId IdType="pubmed">29165333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Zhang Y., Hong M., et al. Molecular typing and characterization of a novel genotype of EV-B93 isolated from Tibet, China. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447049</ArticleId><ArticleId IdType="pubmed">32841272</ArticleId></ArticleIdList></Reference><Reference><Citation>Odoom J.K., Yunus Z., Dunn G., Minor P.D., Martin J. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J. Virol. 2008;82:9179–9190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546908</ArticleId><ArticleId IdType="pubmed">18596089</ArticleId></ArticleIdList></Reference><Reference><Citation>Muslin C., Mac Kain A., Bessaud M., Blondel B., Delpeyroux F. Recombination in enteroviruses, a multi-step modular evolutionary process. Viruses. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6784155</ArticleId><ArticleId IdType="pubmed">31540135</ArticleId></ArticleIdList></Reference><Reference><Citation>M PD. The molecular biology of poliovaccines. J. Gen. Virol. 1992;73</Citation><ArticleIdList><ArticleId IdType="pubmed">1335021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H., Thorley B., Paladin F.J., et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 2004;78:13512–13521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC533948</ArticleId><ArticleId IdType="pubmed">15564462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Yan D., Zhu S., et al. An insight into recombination with enterovirus species C and Nucleotide G-480 reversion from the viewpoint of neurovirulence of vaccine-derived polioviruses. Sci. Rep. 2015;5:17291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658552</ArticleId><ArticleId IdType="pubmed">26603565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, A H. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology. 1999;265:178–184.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600590</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD, Evans DM;, Ferguson M, Schild GC, Westrop G. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. J. Gen. Virol. 1985;66:1159–1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2582084</ArticleId></ArticleIdList></Reference><Reference><Citation>Belnap DM, Jr McDermott BM, Filman DJ, et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc. Natl. Acad. Sci. U. S. A. 2000;97(1):73–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26618</ArticleId><ArticleId IdType="pubmed">10618373</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald S.L., Weldon W.C., Wei L., et al. Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients. Vaccine. 2020;38:3042–3049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11382130</ArticleId><ArticleId IdType="pubmed">32089462</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>